Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuqi Gubengao (FQGBG) is a traditional Chinese medicine (TCM) botanical paste formulation developed by the Yunnan Institute of Materia Medica and Yunnan Baiyao Group, with clinical evaluation conducted in collaboration with Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is composed of three primary herbal ingredients: FuZi (*Aconitum carmichaelii*), Wolfberry (*Lycium barbarum*), and Cinnamon (*Neolitsea cassia*). Fuqi Gubengao is designed to warm kidney yang and is primarily investigated for the treatment of nocturia associated with kidney-yang deficiency syndrome (KYDS). Its therapeutic mechanism is believed to involve the improvement of the hypothalamus-pituitary-adrenal (HPA) axis function and the enhancement of energy metabolism. A Phase I clinical trial (ChiCTR1800015840) has evaluated its safety, tolerability, pharmacokinetics, and metabolomic profiles in healthy adult subjects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuqi Gubengao.